Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22916
Title: Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.
Authors: Doecke, James D;Ward, Larry;Burnham, Samantha C;Villemagne, Victor L;Li, Qiao-Xin;Collins, Steven;Fowler, Christopher J;Manuilova, Ekaterina;Widmann, Monika;Rainey-Smith, Stephanie R;Martins, Ralph N;Masters, Colin L
Affiliation: Australian E-Health Research Centre, CSIRO, Parkville, Melbourne, Victoria, 3052, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine (RMH), The University of Melbourne, Parkville, Melbourne, Victoria, 3052, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Department of Biomedical Sciences, Macquarie University, North Ryde, New South Wales, 2113, Australia
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, 6009, Australia
Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia
Cooperative Research Council for Mental Health, Melbourne, Victoria, 3052, Australia
Australian E-Health Research Centre, CSIRO Health & Biosecurity, Level 5, 901/16 Royal Brisbane & Women's Hospital, Brisbane, Queensland, 4029, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia
Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany
Roche Diagnostics GmbH, Sandhoferstrasse 116, 68305, Mannheim, Germany
Issue Date: 31-Mar-2020
EDate: 2020-03-31
Citation: Alzheimer's research & therapy 2020; 12(1): 36
Abstract: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic-area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22916
DOI: 10.1186/s13195-020-00595-5
ORCID: 0000-0002-5832-9875
PubMed URL: 32234072
Type: Journal Article
Subjects: Alzheimer’s disease
Beta-amyloid
Cerebrospinal fluid
Concordance PET
Tau
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.